About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immatics NV (NQ: IMTX )

9.380 +0.280 (+3.08%)
Streaming Delayed Price Updated: 3:52 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Immatics NV

< Previous 1 2 3 Next >
Immatics Announces Pricing of $150 Million Public Offering
From https://immatics.com/
Via GlobeNewswire
Why Is Cancer-Focused Immatics Stock Trading Lower On Thursday?
Immatics announced updated Phase 1b data for its IMA203 therapy in metastatic melanoma. A deep tumor reduction response was observed in about half of the patients, with positive survival benefits... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Immatics Announces Proposed $150 Million Public Offering
From https://immatics.com/
Via GlobeNewswire
Why Immatics Shares Are Rising Today
Immatics N.V. (NASDAQ: IMTX) shares are trading higher after the company announced  
Via Benzinga
Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024
From https://immatics.com/
Via GlobeNewswire
Biotech Stocks : Are You A Trader Or A Longer Term Investor?
Biotech bull market is intact as indicated by large cap biopharma and the best performing funds. 
Via Talk Markets
Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024
From https://immatics.com/
Via GlobeNewswire
IMTX Stock Earnings: Immatics Beats EPS, Beats Revenue for Q2 2024
IMTX stock results show that Immatics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Immatics Announces Second Quarter 2024 Financial Results and Business Update
From https://immatics.com/
Via GlobeNewswire
Immatics Appoints Alise Reicin to Board of Directors
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Upcoming Oral Presentation at ESMO Congress 2024
From https://immatics.com/
Via GlobeNewswire
Trading SMID Biotech Stocks In A Volatile Market
Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a... 
Via Talk Markets
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Immatics Announces First Quarter 2024 Financial Results and Business Update
From https://immatics.com/
Via GlobeNewswire
IMTX Stock Earnings: Immatics Beats EPS, Beats Revenue for Q4 2023
IMTX stock results show that Immatics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Immatics Announces Full Year 2023 Financial Results and Corporate Update
From https://immatics.com/
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Immatics Announces Pricing of $175 Million Public Offering
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Proposed Public Offering
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Third Quarter 2023 Financial Results and Business Update
From https://immatics.com/
Via GlobeNewswire
Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial
From https://immatics.com/
Via GlobeNewswire
Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy
From https://immatics.com/
Via GlobeNewswire
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
Via ACCESSWIRE
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
From https://immatics.com/
Via GlobeNewswire
Immatics Announces Second Quarter 2023 Financial Results and Business Update
From https://immatics.com/
Via GlobeNewswire
Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors
From https://immatics.com/
Via GlobeNewswire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.